What symptoms and clinical features indicate candidacy for basivertebral nerve ablation (BVNA) in a patient with persistent axial low‑back pain after an osteoporotic vertebral compression fracture?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Symptoms Indicating Candidacy for BVNA

Patients are candidates for basivertebral nerve ablation when they present with chronic axial (midline) low back pain lasting ≥6 months that worsens with sitting, forward flexion, bending, and lifting, improves with standing or walking, and demonstrates Modic type 1 or type 2 endplate changes on MRI after failing conservative management. 1, 2

Core Clinical Features

Pain Characteristics

  • Axial (midline) low back pain - not radicular or leg-dominant pain 2
  • Mechanical pattern: worse with sitting, forward flexion, bending, lifting, and driving 3
  • Relief pattern: improves with standing, walking, or lying down 3
  • Duration: minimum 6 months of persistent symptoms 1, 4

Essential Imaging Findings

  • Modic type 1 changes (bone marrow edema on MRI - hyperintense on T2, hypointense on T1) OR
  • Modic type 2 changes (fatty marrow replacement - hyperintense on both T1 and T2) 5, 1, 2
  • Changes must be present at the vertebral endplates corresponding to the pain location 3

Treatment Failure Requirements

Patients must have failed conservative management before BVNA consideration 1. This includes:

  • Nonsteroidal anti-inflammatory drugs
  • Physical therapy
  • Activity modification
  • Other interventional procedures (epidural injections, facet interventions, medial branch blocks) 3

The 2025 BMJ guideline 6 strongly recommends against epidural injections and radiofrequency ablation for chronic axial spine pain, which reinforces that patients failing these traditional interventions may benefit from BVNA as a distinct treatment targeting a different pain generator.

Expanding Indications

Recent evidence 5, 7, 3 demonstrates BVNA efficacy beyond original trial criteria:

  • Post-fusion patients with persistent vertebrogenic pain at adjacent or fused levels 3
  • Advanced osteopenia (T-score -2.2) without fracture 7
  • Multilevel Modic changes 4

Critical Exclusion Criteria

  • Active vertebral compression fracture - this is the key distinction from your clinical scenario
  • Neurologic deficits requiring surgical decompression
  • Active spinal infection
  • Uncorrectable coagulopathy 1

Important Clinical Distinction

BVNA addresses vertebrogenic pain from endplate degeneration, NOT acute fracture pain. The evidence provided focuses on vertebral augmentation (vertebroplasty/kyphoplasty) for osteoporotic compression fractures 8, 9, 8, which is a completely different indication and procedure than BVNA.

For a patient with persistent axial pain AFTER an osteoporotic vertebral compression fracture has healed, BVNA candidacy would require:

  1. Fracture healing confirmed on imaging (typically 3+ months post-fracture) 8
  2. Persistent midline mechanical back pain despite fracture healing
  3. Development or persistence of Modic changes at the affected or adjacent levels
  4. Pain pattern consistent with vertebrogenic pain (mechanical, axial, worse with flexion)
  5. Failure of conservative management including any vertebral augmentation if performed

The case report of BVNA in advanced osteopenia 7 demonstrates safety in metabolic bone disease when no acute fracture is present, suggesting potential applicability in post-fracture scenarios once healing is complete and vertebrogenic pain persists.

Related Questions

What is vertebrogenic pain?
What are the considerations and procedures for a patient with chronic back pain undergoing basivertebral nerve ablation?
Is thermal destruction of the intraosseous basivertebral nerve (TRML DSTRJ IOS BVN) medically necessary for a patient with vertebrogenic low back pain?
Is a patient with 4 mm disc bulges at L3‑5 and L5‑S1 causing mild anterior thecal‑sac effacement, who underwent bilateral facet ablation 12 days ago, still a suitable candidate for sacrocolpopexy?
How should a patient 12 days after lumbar facet ablation who has mild hip and buttock spasms be managed preoperatively before sacrocolpopexy?
Can GLP‑1 receptor agonists (e.g., exenatide, liraglutide, dulaglutide, semaglutide, tirzepatide) cause permanent vision loss?
Should nitrofurantoin (Macrobid) be prescribed to an elderly patient only if creatinine clearance is ≥60 mL/min and there are no contraindications such as pulmonary, hepatic, or neurologic disease?
Is non‑arteritic anterior ischemic optic neuropathy (NAION) a risk associated with glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) such as exenatide, liraglutide, dulaglutide, or semaglutide?
In a patient with persistent knee pain and negative knee X‑ray and CT, is MRI the next step in management?
How should I interpret the hormone labs of a 15-year-old transgender female on estradiol and spironolactone, given estradiol within target range, elevated testosterone, elevated follicle-stimulating hormone, and low luteinizing hormone?
How should an anaphylactic reaction presenting with lip angioedema and throat tightness due to a known allergen be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.